<![CDATA[Abstracts to Be Presented at EHA]]>

<![CDATA[Abstracts to Be Presented at EHA]]>Abstracts to Be Presented at EHA

Daratumumab
Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Preliminary Efficacy and Pharmacokinetics Data from a Dose-Escalation Phase I/II Study (oral presentation)

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis

Towards Personalized Medicine Using a Novel Preclinical Model: Identifying Daratumumab as Effective Treatment for Multiple Myeloma

]]>https://dev.proinvestor.com/forum/topic/448422/abstracts-to-be-presented-at-ehaRSS for NodeFri, 19 Jun 2026 14:38:43 GMTThu, 17 May 2012 09:19:42 GMT60